Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot ...
Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million. Adjusted EPS of 83 cents, beating the consensus of 67 cents. Revenue from ...
StockStory.org on MSN
Penumbra (NYSE:PEN): Strongest Q4 results from the medical devices & supplies - cardiology, neurology, vascular group
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Penumbra (NYSE:PEN) and its peers. The medical ...
Penumbra has benefited from renewed enthusiasm around the company's neuro and peripheral thrombectomy platforms, and the company recently launched the Lightning Flash. Management is making a big bet ...
Boston Scientific has agreed to acquire Penumbra in a deal worth around $14.5bn, a move that will expand the medtech giant’s offerings in ‘fast-growing segments’ within the vascular care space. Under ...
9 analysts have expressed a variety of opinions on Penumbra (NYSE:PEN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results